Open innovation in new drug research: the Indian perspective

This article sketches open innovation strategies pursued by eight Indian pharmaceutical firms and provides an account of strategic flexibility charted by firms in the wake of changes in the legislative environment. The findings examined through the lens of open innovation and dynamic capabilities identifies ‘technological competencies’ and ‘funding’ as two very important reasons, which push the traditionally closed R&D firms to pursue open innovation. Within the dynamic capabilities framework, the findings suggest that resources and competencies play a vital role in enabling open innovation in the complex new drug research setting.